Serveur d'exploration sur les relations entre la France et l'Australie - Analysis (Allemagne)

Index « Auteurs » - entrée « P. Nash »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
P. Napiorkowski < P. Nash < P. Nathan  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 3.
Ident.Authors (with country if any)Title
001F18 (2009) M. Matucci-Cerinic [Italie] ; Y. Allanore [France] ; L. Czirják [Hongrie] ; A. Tyndall [Suisse] ; U. Müller-Ladner [Allemagne] ; C. Denton [Royaume-Uni] ; G. Valentini [Italie] ; O. Distler [Suisse] ; K. Fligelstone ; A. Tyrrel-Kennedy ; D. Farge [France] ; O. Kowal-Bielecka [Pologne] ; F. Van Den Hoogen [Pays-Bas] ; M. Cutolo [Italie] ; P D Sampaio-Barros [Brésil] ; P. Nash [Australie] ; K. Takehara [Japon] ; D E Furst [États-Unis]The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy
002725 (2004) L B A. Van De Putte [Pays-Bas] ; C. Atkins [Canada] ; M. Malaise [Belgique] ; J. Sany [France] ; A S Russell [Canada] ; P L C M. Van Riel [Pays-Bas] ; L. Settas [Grèce] ; J W Bijlsma [Pays-Bas] ; S. Todesco [Italie] ; M. Dougados [France] ; P. Nash [Australie] ; P. Emery [Royaume-Uni] ; N. Walter [Allemagne] ; M. Kaul [Allemagne] ; S. Fischkoff [États-Unis] ; H. Kupper [Allemagne]Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
002769 (2004) L. B. A. Van De Putte [Pays-Bas] ; C. Atkins ; M. Malaise [Belgique] ; J. Sany [France] ; A. S. Russell [Canada] ; P. L. C. M. Van Riel [Pays-Bas] ; L. Settas [Grèce] ; J. W. Bijlsma [Pays-Bas] ; S. Todesco [Italie] ; M. Dougados [France] ; P. Nash [Australie] ; P. Emery [Royaume-Uni] ; N. Walter [Allemagne] ; M. Kaul [Allemagne] ; S. Fischkoff [États-Unis] ; H. Kupper [Allemagne]Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying anti rheumatic drug treatment has failed

List of associated KwdEn.i

Nombre de
documents
Descripteur
3Rheumatology
2Adalimumab
2American college
2Arthritis
2Arthritis rheum
2Monoclonal antibody
2Rheum
2Rheumatoid arthritis
1ACR, American College of Rheumatology
1ANA, antinuclear antibody
1Abbott laboratories
1Adalimumab monotherapy
1Adalimumab treatment groups
1Adverse event
1Adverse events
1Antinuclear antibodies
1Antirheumatic drugs
1Arthritis rheum bodolay
1Arthritis rheum cutolo
1Atkins
1Available datasets
1Baseline
1Baseline value
1CRP, C reactive protein
1Capillaroscopic
1Capillaroscopic pattern
1Chronic
1Classification criteria
1Clin
1Concomitant
1Concomitant methotrexate
1Connective
1Connective tissue disease
1Critical importance
1DAS, disease activity score
1DMARDs, disease modifying antirheumatic drugs
1Delphi technique
1Diagnostic criteria
1Diffuse cutaneous
1Disability index
1Disease activity
1Disease activity score
1Disease evolution
1Dmard
1Dmards
1Dos
1Drug
1ESR, erythrocyte sedimentation rate
1EULAR, European League Against Rheumatism
1Earliest phase
1Early diagnosis
1Early disease
1Early treatment
1Effective drugs
1Erythrocyte sedimentation rate
1Eular
1Eular response
1Eular response rates
1Eular scleroderma trial
1European league
1Good eular response
1Gordian knot
1HAQ DI, Disability Index of the Health Assessment Questionnaire
1Health assessment questionnaire
1Human
1Injection site reaction
1Internal medicine
1Limit patient evaluation
1Limited cutaneous
1MTX, methotrexate
1Matucci cerinic
1Mctd
1Methotrexate
1Monoclonal
1Monotherapy
1NSAIDs, non-steroidal anti-inflammatory drugs
1Other week
1Patient assessment
1Percentage change
1Placebo
1Predictor
1Preliminary criteria
1Previous dmard treatment
1Primary efficacy
1Primary phenomenon
1Prospective studies
1Provisional criteria
1Puffy fingers
1Putte
1RA, rheumatoid arthritis
1Randomised
1Reactive protein
1Regimen
1Reliable predictors
1Research group
1Respective adalimumab doses
1Response criteria
1Response rates
1Rheumatoid
1Rheumatol

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "P. Nash" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i  \
                -Sk "P. Nash" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Allemagne
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    P. Nash
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024